ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA

ImmuPharma PLC (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist discovery and development pharmaceutical company is pleased to provide an update on the development status of its Lupus drug candidate Lupuzor™